National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Fluticasone furoate/ umeclidinium/ vilantero (Trelegy™ Ellipta™)

Trelegy™ Ellipta™ which is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA.


NCPE Assessment Process Complete
Rapid review commissioned 30/04/2018
Rapid review completed 18/06/2018
Rapid Review outcome A full pharmacoeconomic assessment is not recommended. The NCPE recommends that Trelegy™ Ellipta™ be considered for reimbursement in accordance with the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.



The HSE has approved reimbursement; August 2018